Trial Profile

A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Jun 2022 Results reporting long term relapse-risk-reduction efficacy and safety data from two clinical studies: PREVENT (NCT01892345) and its OLE (NCT02003144) presented at the 8th Congress of the European Academy of Neurology
06 Apr 2022 Status changed from active, no longer recruiting to completed.
01 Mar 2022 Results from PREVENT and its open-label extension study (NCT01892345, NCT02003144) published in the Multiple Sclerosis Journal

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com